| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.17 | 3e-07 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.15 | 1e-06 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.17 | 2e-06 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.16 | 2e-06 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.15 | 3e-06 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.15 | 3e-06 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | -0.16 | 4e-06 |
| mRNA | AZD-2281 | CTRPv2 | pan-cancer | AAC | -0.16 | 7e-06 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.15 | 7e-06 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.13 | 1e-05 |